Trial | NCT00951574  Report issue

Title

Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)
Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium). A Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study.

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    1166
In this phase III, multicenter study, 1200 patients with lung, breast, gastrointestinal (stomach, colon-rectum, pancreas), ovarian or head and neck cancer undergoing chemotherapy will be randomly assigned (at the beginning of cytotoxic therapy) in a 2:1 ratio and in double-blind conditions to a treatment with subcutaneous low molecular weight heparin (nadroparin calcium, one injection/day) or placebo for the overall duration of chemotherapy or up to a maximum of 4 months (+/- 10 days).
Study Started
Oct 31
2003
Primary Completion
May 31
2007
Study Completion
Jul 31
2008
Last Update
Feb 01
2012
Estimate

Drug Nadroparin calcium

Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).

Drug saline solution (placebo)

Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).

saline solution Placebo Comparator

Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours).

nadroparin calcium Experimental

Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).

Criteria 

INCLUSION CRITERIA:

both sexes;aged>18 years;
suffering from different types of malignancies(lung, breast,gastric,colon- rectum,pancreatic,ovarian,head and neck cancer)undergoing systemic chemotherapy,
having signed Informed Consent prior to initiation of any study procedure.

EXCLUSION CRITERIA:

adjuvant and neo-adjuvant chemotherapy;
objectively confirmed venous or arterial thromboembolism in the last three months;
antithrombotic treatment for other indications;
life expectancy of less than 3 months;
Performance Status>2(ECOG);
active bleeding or bleedings in the last four weeks requiring hospitalization,transfusion or surgical intervention;
bleeding diathesis(prothrombin time<70% or activated partial thromboplastin time ratio>1.3),or platelet count<50x10^9/L;
cerebrovascular hemorrhage in the last six months;
known active gastric or duodenal ulcer;
known cerebral metastasis;
cerebral aneurysm;
III-IV grade diabetic retinopathy;
severe and uncontrolled hypertension(systolic blood pressure>180 mmHg or diastolic blood pressure>110 mmHg);
chronic atrial fibrillation;
acute endocarditis;
acute pancreatitis;
known hypersensitivity to unfractionated heparin or LMWH;
previous occurrence of heparin-induced thrombocytopenia;
renal impairment (dependent on dialysis or creatinine higher than 2.5mg%);
liver insufficiency (alanine aminotransferase,aspartate aminotransferase,alkaline phosphatase levels>3 times the upper limit of the normal ranges and/or total bilirubin >3.0 mg/ml);
pregnancy or childbearing potential without adequate contraception;
treatment with other investigational drugs or patient inclusion in other clinical trials;
patients who are unable to fulfill the study requirements in terms of visits/compliance to treatment.
No Results Posted